SNDX-5613 (Revumenib): Mechanism of Action

SNDX-5613 (Revumenib) MOA：Targeting Menin/HOX Pathway for Acute Leukemia

🎯 check SNDX-5613 (Revumenib) product page

SNDX-5613 is a menin inhibitor. It affects MLL/NPM1 signaling by enhancing CLL-1 expression, promoting CAR T cell immunity.

Primary Applications and Mechanism of Action

Jump to: